Evidence map›Paper›PMID 42238020›Full record

ArticleJTO clinical and research reports2026

Risk Factors for Developing Venous Thromboembolism in Patients With Advanced ALK-Rearranged NSCLC.

Caroline Kamali, Georgios Tsakonas, Rolf Lewensohn, Lena Kanter, Hanna Vikman, Anders Berglund, Elena Nedbaylo, Per Hydbring, Kristina Viktorsson, Luigi De Petris and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Caroline KamaliDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Georgios TsakonasDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Rolf LewensohnDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Lena KanterDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Hanna VikmanEpiStat AB, Uppsala, Sweden.
Anders BerglundEpiStat AB, Uppsala, Sweden.
Elena NedbayloTheme Cancer, Medical Unit Head and Neck, Lung and Skin Tumors, Thoracic Oncology Center, Karolinska University Hospital, Stockholm, Sweden.
Per HydbringDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Kristina ViktorssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Luigi De PetrisDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Simon EkmanDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Patients with NSCLC have an increased risk of developing venous thromboembolism (VTE), a condition associated with a poorer prognosis. Those with Methods: We retrospectively analyzed patients with advanced ALK-positive NSCLC treated at Karolinska University Hospital from 2009 to 2021. VTE events were recorded from 90 days before histologic cancer diagnosis to death or end of follow-up. The impact of VTE on survival was assessed using a time-dependent Cox model, and risk factors were evaluated using Fine-Gray competing risk regression. Results: A total of 97 patients were included, of whom 35 (36.1%) developed VTE. Pulmonary embolism accounted for 24 cases (68.6%), with 16 events (45.7%) occurring more than 6 months after treatment initiation. The median time from diagnosis to the first clot was 167 days. Patients with VTE had a 3.43-fold increased risk of death. Competing risk regression analysis revealed that the presence of baseline adrenal metastasis (hazard ratio [HR] = 2.92, 95% confidence interval [CI]: 1.19-7.16), leukocyte count more than 11 × 10 Conclusion: In advanced ALK-positive NSCLC, baseline adrenal metastases, leukocytosis, and anemia were associated with increased VTE risk and may warrant heightened clinical vigilance.

Indexed as

Advanced diseaseAnaplastic lymphoma kinase translocationEML4-ALK fusion variantsNon–small cell lung cancerVenous thromboembolism

Identifiers

PMID42238020
PMCPMC13226909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.